Clinical Trial Update: Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

The Phase IIb/III trial of TG4010 immunotherapy in stage IV non-small cell lung cancer was terminated. No efficacy results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TG4010 (MVA-MUC1-IL-2 therapeutic cancer vaccine)

Snippet

Sponsor: Transgene | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2, Phase 3 | Status: TERMINATED